In many developing countries it is a difficult and complex challenge to ensure that sufficient treatment is made available for all. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. It is our goal to develop better medical solutions that can radically improve the lives of people with diabetes, haemophilia and other conditions. We therefore depend on efficient protection of our intellectual property rights. In Novo Nordisk we aim to ensure that our innovations contribute to better health for people across the world.
Novo Nordisk is the largest provider of human insulin worldwide. Human insulin is an essential drug on the WHO Model List of Essential Medicines and has been off patent for many years. This means human insulin is in the public domain and can be manufactured in any part of the world without the need of a license to any patents. Novo Nordisk makes human insulin available to the world's least developed countries - LDCs (as defined by the United Nations) through our Access to Insulin Commitment where human insulin is offered at a maximum of 20% of the realised price in Europe, the US, Canada and Japan. In many other low- and middle-income countries, Novo Nordisk sells human insulin at equally low prices through large government tenders reaching millions of people with diabetes. As a consequence, we do not view non-exclusive voluntary licensing as the appropriate tool to ensure access to essential diabetes medicines like human insulin.
Corporate Vice President
+45 3079 1822